openPR Logo
Press release

Bronchiectasis Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top players are Insmed Corporation, Bayer, Santhera Pharmaceuticals, Insmed Incorporated, Zambon, Alitair Pharmaceuticals

06-06-2019 01:32 PM CET | Health & Medicine

Press release from: Pharma Proff

Bronchiectasis Therapeutics Pipeline to Witness Significant

Bronchiectasis, a chronic airways infection, affects lungs and widens bronchial trees. This leads to gradual loss of mucus clearing ability, which increases growth of bacteria. Bronchiectasis can lead to serious health problems such as respiratory failure, heart failure, and atelectasis. The disease often begins in childhood and can be acquired or congenital. Signs and symptoms of bronchiectasis are excessive tiredness or difficulty in concentrating and breathing, anxiety, cough incontinence, depression, coughing up blood, chest pain, and joint pain. Bronchiectasis can further be diagnosed through chest X-ray, blood tests, computerized tomography (CT) scan, and lung function tests such as bronchoscopy and genetic blood tests.

Download the sample report: https://www.pharmaproff.com/request-sample/1218

According to the research, many drugs being developed for bronchiectasis are administered mainly through pumps. It has been found that pulmonary route of administration is more effective as the disease affects pulmonary organs. Through this route, drug reached to the target site faster as compared to other route of administration.

Browse Detailed Report at: https://www.pharmaproff.com/report/bronchiectasis-therapeutics-pipeline-analysis

Companies that are involved in developing therapeutics for bronchiectasis have shown positive clinical results in various phases of drug development. For instance, in 2017, Insmed Incorporated revealed topline results for phase III research of Amikacin Liposome Inhalation Suspension (ALIS) in adult patients suffering from diseases caused by mycobacterium, including bronchiectasis.

Since, there is no marketed product for bronchiectasis, companies are actively seeking designation grants to accelerate the process of development. For instance, the U.S. Food and Drug Administration (USFDA) granted Orphan Drug Designation to Ciprofloxacin dry powder for inhalation, developed by Bayer AG. The designation and various strategic developments of companies aid in the progress of better medication.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1218

Aradigm Corporation, Bayer AG, Santhera Pharmaceuticals Holding AG, Insmed Incorporated, Zambon S.p.A., and Alitair Pharmaceuticals Inc. are some of the companies involved in the development of bronchiectasis therapeutics.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bronchiectasis Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top players are Insmed Corporation, Bayer, Santhera Pharmaceuticals, Insmed Incorporated, Zambon, Alitair Pharmaceuticals here

News-ID: 1766730 • Views: 501

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Bronchiectasis

Bronchiectasis Global Market Research Report 2025
Bronchiectasis Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/bronchiectasis-market/80987 The report firstly introduced the Bronchiectasis basics: definitions, classifications, applications and market overview; product
Bronchiectasis Therapeutics Pipeline - Key Players Analysis Aradigm Corporation, …
The study analysed that the Bronchiectasis therapeutics pipeline comprises approximately 13 drug candidates in different stages of development. Bronchiectasis is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of lungs. Bronchiectasis usually is the result of an infection or other condition that injures the walls of airways or prevents the airways from
Bronchiectasis Therapeutics Analysis - Clinical Trials & Results, Collaboration …
The study analysed that the Bronchiectasis therapeutics pipeline comprises approximately 13 drug candidates in different stages of development. Bronchiectasis is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of lungs. Bronchiectasis usually is the result of an infection or other condition that injures the walls of airways or prevents the airways
Bronchiectasis Treatment Market Trends Detailed in New Research Report 2025
Bronchiectasis refers to a condition characterized by damaged airways (tubes) and affect their ability to clear out the mucus. This deposition of mucus leads to bacterial infections and hence resulting in serious and repeated lung infections. Bronchiectasis is a long term condition resulting in serious health conditions such as heart failure and respiratory failure. Mucus producing cough is the major symptom of this condition. Request Report for Table of Contents
Bronchiectasis Market To Discern Magnified Growth During 2025
Bronchiectasis is a chronic and life-threatening disease, wherein parts of airways of lungs are permanently enlarged. This condition damages the bronchial tubes of lungs permanently and also widens, and thickens them. Inflammation and infection in the bronchi leads to this condition. The severity of bronchiectasis symptoms may vary widely. The most common symptom of bronchiectasis is breathlessness i.e., difficulty in breathing or feeling short of breath, frequent chest infections, and
Bronchiectasis Treatment Market Foraying into Emerging Economies 2017 - 2025
Bronchiectasis refers to a condition characterized by damaged airways (tubes) and affect their ability to clear out the mucus. This deposition of mucus leads to bacterial infections and hence resulting in serious and repeated lung infections. Bronchiectasis is a long term condition resulting in serious health conditions such as heart failure and respiratory failure. Mucus producing cough is the major symptom of this condition. Request for Table of Contents @ https://www.persistencemarketresearch.com/toc/21037